Frailty in hospitalised heart failure patients and the effects of heart failure specific pharmacotherapy in frail heart failure patients
Not Applicable
Active, not recruiting
- Conditions
- heart failurefrailtyhospitalised patientsCardiovascular - Other cardiovascular diseases
- Registration Number
- ACTRN12622000013763
- Lead Sponsor
- Flinders Medical Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Active, not recruiting
- Sex
- All
- Target Recruitment
- 2126
Inclusion Criteria
All patients 18 years or over who were admitted with a diagnosis of heart failure and admitted between 1 January 2013 to 31 December 2020 at Flinders Medical Centre (FMC) and Royal Adelaide Hospital (RAH), Adelaide, South Australia
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the prevalence of frailty as defined by the Hospital Frailty Risk Score (HFRS) in patients hospitalised with heart failure.[At the time of hospitalisation];To determine any differences in the days alive and out of hospital (DAOH) in frail heart failure patients who received heart failure specific pharmacotherapy when compared to those who did not recieve treatment by data-linkage to medical records of participants.[At 90 days following discharge from hospital]
- Secondary Outcome Measures
Name Time Method To determine any difference in mortality at 30-days following discharge among frail heart failure patients who received heart failure specific pharmacotherapy compared to those who did not receive treatment[At 30-days following discharge from hospital.];To determine any differences in 30-day readmissions between frail hospitalised heart failure patients who received heart failure specific pharmacotherapy by data linkage to medical records of participants.[At 30-days following discharge from hospital]